

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/189811 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) C12N 15/63 (2006.01)

(21) International Application Number:
PCT/GB2022/050649

(22) International Filing Date:
14 March 2022 (14.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2103470.7 12 March 2021 (12.03.2021) GB
PCT/GB2021/050633
12 March 2021 (12.03.2021) GB
PCT/GB2021/051668
30 June 2021 (30.06.2021) GB

(71) Applicants: **THE UNIVERSITY OF BRISTOL** [GB/GB]; Beacon House, Queens Road, Bristol BS8 1QU (GB). **SYNCONA INVESTMENT MANAGEMENT LIMITED** [GB/GB]; 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). **PURESPRING THERAPEUTICS LIMITED** [GB/GB]; 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB).

(72) Inventors: **SALEEM-UDDIN, Moin**; c/o The University of Bristol, Beacon House, Queens Road, Bristol BS8 1QU (GB). **WELSH, Gavin**; c/o The University of Bristol, Beacon House, Queens Road, Bristol BS8 1QU (GB). **KUZMUK, Valeryia**; c/o Purespring Therapeutics, 8 Bloomsbury street, 2nd Floor, London WC1B 3SR (GB). **GRIF-FITH, Alan William**; c/o Purespring Therapeutics, 8 Bloomsbury street, 2nd Floor, London WC1B 3SR (GB).

(74) Agent: **D YOUNG & CO LLP**; 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

WO 2022/189811 A1

(54) Title: MINIMAL NEPHRIN PROMOTER

(57) Abstract: A promoter comprising (i) a nucleotide sequence having at least 70% identity to SEQ ID NO: 4 or 17 and wherein the promoter has a length of about 1.1 kb or less.